Dyadic International, Inc., a global biotechnology company, has announced a strategic rebrand to Dyadic Applied BioSolutions. This change reflects the company's focus on commercializing non-therapeutic proteins using its proprietary C1 and Dapibus™ gene expression platforms. The rebrand marks a pivotal step in transitioning from a research-driven organization to a commercially focused enterprise, emphasizing applied biotechnology solutions for various industries.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。